Severe acquired hypertriglyceridemia following COVID-19

BMJ Case Rep. 2021 Nov 11;14(11):e246698. doi: 10.1136/bcr-2021-246698.

Abstract

Severe hypertriglyceridemia is a major risk factor for acute pancreatitis. In exceptional cases, it is caused by plasma components inhibiting lipoprotein lipase activity. This phenomenon is predominantly associated with autoimmune diseases. Here, we report a case of severe hypertriglyceridemia due to a transient reduction in lipoprotein lipase activity following an episode of COVID-19 in an otherwise healthy 45-year-old woman. The lipoprotein lipase activity of the patient was markedly reduced compared with a healthy control and did recover to 20% of the healthy control's lipoprotein lipase activity 5 months after the COVID-19 episode. Mixing tests substantiated reduced lipolytic capacity in the presence of the patient's plasma at presentation compared with a homozygous lipoprotein lipase-deficient control, which was no longer present at follow-up. Western blotting confirmed that the quantity of lipoprotein lipase was not aberrant. Fibrate treatment and a strict hypolipidemic diet improved the patient's symptoms and triglyceride levels.

Keywords: COVID-19; lipid disorders; pancreatitis.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • COVID-19*
  • Female
  • Humans
  • Hypertriglyceridemia* / complications
  • Middle Aged
  • Pancreatitis* / etiology
  • SARS-CoV-2
  • Triglycerides

Substances

  • Triglycerides